In Brief: Palladone Withdrawn | The Medical Letter Inc.

The Medical Letter on Drugs and Therapeutics

FROM
ISSUE

1214

August 1, 2005

View Complete Issue Table of Contents 2019

In Brief: Palladone Withdrawn

Download PDF: US English

Show Related
Terms Hide Related
Terms

View Complete Issue

Send Article Feedback

Med Lett Drugs Ther. 2005 Aug 1;47(1214):61

Disclosures

Objective(s)

Select a term to see related articles abuse Addiction Analgesia Analgesics Avinza chronic pain Dilaudid Drug abuse Drug dependence Duragesic Fentanyl Hydrocodone Hydromorphone Kadian Morphine MS Contin opioids Oramorph Oramorph SR Oxycontin pain Palladone

The Medical Letter review of Palladone (hydromorphone HCl) extended-release capsules (March 14, 2005) warned that a lethal dose could be released if the new formulation was taken with alcohol. Because of that risk, the FDA asked the manufacturer (Purdue) to withdraw the drug from the market (FDA News. July 13, 2005; FDC Reports – “The Pink Sheet” July 18, 2005; 67:3).

The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

This article has been freely provided.